ROLE OF COMMUNITY PARAMEDICINE IN NON-EMERGENCY PRESENTATIONS
Dr Robbie King
Lecturer in paramedicine and researcher, Australian Catholic University (ACU) Brisbane &
Senior Advanced Care Paramedic/Community Paramedic,
Sunshine Coast District, Birtinya Station,
Queensland Ambulance Service, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Queensland | November 2024
Dr Robbie King is a Lecturer in paramedicine and researcher at the Australian Catholic University (ACU) Brisbane. He also continues to provide clinical care as a registered paramedic for community members served by a jurisdictional ambulance service. Dr King has gained significant experience working in an advanced practice, community paramedic style role, holding expert clinical insight into the nuances of paramedic-led community-based healthcare for non-emergency presentations. This often involves adopting a biopsychosocial approach, rather than following the biomedical model more associated with emergency medicine and paramedic culture.
To encourage a patient-centred approach to paramedic-led healthcare by exploring the unmet needs of people requesting unscheduled emergency ambulance care, Dr King advocates for greater consumer engagement in paramedic research. He completed his PhD in early 2024 which explored the patient perspective of paramedic-led healthcare when patients were not transported to hospital. This research generated a theory that describes a process of patients ‘restoring self-efficacy’ when their vulnerabilities are validated, and they receive clinically competent and compassionate care.
Dr King has presented at professional symposium internationally, and in Australia where he continues to encourage greater consumer involvement in research to inform development of paramedic education and ambulance service models of healthcare delivery. Dr King is a Fellow of the Australasian College of Paramedicine and member of various professional research and Community Paramedic working groups. His research focus includes exploring the role of community paramedics in improving health literacy, self-efficacy, and addressing the psychosocial needs of patients requesting emergency ambulance services.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Therapies for chronic myeloid leukaemia
Professor Tim Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times.
-
Health and economic burden of interstitial lung diseases
Dr Cox’s main research interests focus on respiratory diseases and primarily on the economic burden and economic evaluation of interventions and treatments for their management. She earned her PhD from the University of Tasmania where her doctoral research examined the health and economic burden of idiopathic pulmonary fibrosis (IPF) in Australia, one component of the NHMRC Centre for Research Excellence for Pulmonary Fibrosis, a national project implemented alongside the Australian IPF Registry and the Lung Foundation Australia. This research provided the first epidemiological profile and first costing estimates of the economic burden of the disease in Australia, providing essential evidence for health service reimbursement policies.
